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ABSTRACT
THE TRANSCRIPTIONAL EFFECTS OF PHOTOBIOMODULATION IN AN IN VITRO
MODEL OF DIABETIC RETINOPATHY

by
Hannah Fisher

The University of Wisconsin-Milwaukee, 2016
Under the Supervision of Janis T. Eells, Ph.D

Diabetic retinopathy (DR) is the most common complication of diabetes mellitus and a
leading cause of blindness. The pathophysiology of DR is complicated, involving
inflammation, oxidative stress, retinal vascular proliferation, and vascular degeneration.
Symptomatically, the growth and subsequent rupture of vessels within the frame of view
leads to the development of vision loss and eventual blindness. Prior to the
development of symptoms, oxidative stress involved in DR leads to the activation of the
transcription factor, nuclear factor-B (NF-B), resulting in the excess production of
vascular endothelial growth factor (VEGF) and intracellular adhesion molecule-1 (ICAM1), proteins involved in vascular development and immune dysregulation, respectively.
The most common therapeutic approach for DR utilizes anti-VEGF agents to reduce
vascular proliferation. These treatments are expensive, invasive, frequently ineffective,
and have numerous adverse effects, such as retinal detachment, infection, and
inflammation inside the eye. A non-invasive alternative therapy is clearly needed.
Photobiomodulation (PBM) using far-red to near infrared (NIR) light has been shown to
reduce oxidative stress and inflammation in vitro and in vivo and is an ideal candidate
for an alternative therapy. Indeed, PBM slows the progression of DR in animal models
ii

via attenuation of oxidative stress and by reducing the relative level of ICAM-1. We
hypothesize that PBM will reduce the activity of NF-B and reduce the production of
VEGF and ICAM-1 in an in vitro model of DR. To test this hypothesis, we used an in
vitro model system of cultured retinal Müller glial cells grown in normal (5 mM) or high
(25 mM) glucose conditions for either 3 or 6 days to simulate normoglycemia and
hyperglycemia. Cultures were treated with 670 nm light emitting diode (LED) (180
seconds at 25 mW/cm2; 4.5 J/cm2) or no light (sham) for 3 or 5 days. NF-B activity and
ICAM-1 concentrations were significantly increased under high glucose conditions, as
measured by a dual luciferase assay or western blot, respectively. Treatment with 670
nm LED significantly reduced NF-B activity of high glucose culture cells to values
comparable to transcriptional activity measured under normoglycemic condition and
decreased the level of ICAM-1. VEGF concentrations were not affected by high glucose
or PBM. These data are in partial support of our central hypothesis that in an in vitro
model of DR, 670 nm light will reduce activation of NF-B, and reduce the synthesis of
ICAM-1 and VEGF. The lack of an observable effect of hyperglycemia or PBM on
VEGF concentrations indicates that the stimulation of VEGF secretion requires the
activation of additional signaling pathways not induced by high glucose alone.
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I.

INTRODUCTION

Diabetes
Over 29 million people in the United States are currently diagnosed with diabetes
mellitus (CDC 2014). Diabetes mellitus is a metabolic disease in which the body is
unable to regulate glucose utilization, resulting in an asymptomatic increase in blood
glucose concentrations referred to as hyperglycemia. Two pancreatic hormones, insulin
and glucagon, are important in the regulation of blood glucose concentrations.
Glucagon signals for the release of glucose into circulation, whereas insulin promotes
the uptake of glucose. In diabetes, though, glucose utilization is impaired in one of two
ways: by a lack of insulin production or by a defect in the body’s response to insulin.
Under normal conditions, insulin is released by the pancreas in response to a rise in
concentrations of glucose, free fatty acids, amino acids, and incretins. Within the
pancreas, insulin is produced by pancreatic β-cells and secreted into the blood stream
in response to elevated glucose concentrations. Once in the blood stream, insulin
signals skeletal muscle and adipose tissue to take up glucose, restoring homeostasis.
Glucose is then oxidized via the tricarboxylic acid cycle and mitochondrial electron
transport chain to produce adenosine triphosphate (ATP), the primary cellular energy
source. Inadequate insulin production or insulin signaling inhibits these processes,
resulting in hyperglycemia.

Although diabetes mellitus is incurable, alterations to lifestyle and drug therapies can
assist in the maintenance of stable blood glucose concentrations. Treatment options are
dependent on whether an individual is diagnosed with Type 1 or Type 2 diabetes. Type
1

1 diabetes results from an autoimmune induced destruction of the pancreatic β-cells,
which eliminates insulin production. Therefore, treatment of type 1 diabetes requires
insulin therapy throughout a patient’s life. Type 2 diabetes, however, is associated with
insulin resistance and/or abnormal insulin secretion (Gullausseau et al. 2008). Unlike
type 1 diabetes, type 2 diabetes can be managed, to some degree, by lifestyle changes,
such as dietary modifications. Most type 2 diabetics, though, will also require insulin or
oral hyperglycemic drug therapy to regulate blood glucose levels.

Despite lifestyle changes and/or drug interventions to regulate blood glucose
concentrations, long-term metabolic complications commonly develop in patients with
either type 1 or type 2 diabetes. Diabetic complications occur with sustained tissue
exposure to high circulating glucose and lead to micro- and macro-vascular
complications throughout the body (Yamaoto et al. 2001, Aubert et al. 2014, Wu and
Juurlink 2002, Wendt et al. 2003). Macrovascular damage increases the prevalence of
heart disease, stroke, and peripheral arterial disease. Microvascular damage
contributes to diabetic retinopathy (DR), neuropathy and nephropathy in diabetic
patients. Cardiovascular disease, nephropathy, neuropathy, and DR are all considered
major complications of diabetes.

The most common diabetic complication, DR, is associated with vision loss as a result
of vasculature development and rupture within the retina of the eye. A pathological
increase in oxidative stress, promoted by mitochondrial dysfunction, increased signaling
through the advanced glycation endproducts (AGE) and receptor of AGE (RAGE)
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pathway, as well as increased activation of protein kinase C (PKC) are important for the
development of DR (Kanwar et al. 2009, Wu and Juurlink 2002, Xia et al. 1994, Geralds
et al. 2009). The symptomatic changes, which occur as a result of these pathways, take
place in the retina.

Anatomy of the Eye
Anatomy of the Retina
A healthy retina is essential for good vision. This light-sensitive tissue is located at the
back of the eye and is the site of vision transduction. The neural retina is arranged in
three cell layers. The rod and cone photoreceptor cells, which are responsible for visual
transduction, are arranged in a layer against the back of the eyeball. The second layer
of cells, known as the inner nuclear layer, contains bipolar cells, horizontal cells, and
amacrine cells. The surface layer of the retina is comprised of ganglion cells. The
ganglion cell axons form the optic nerve which relays information to the brain. There are
two synaptic regions in the retina: (1) the outer plexiform layer which contains the
photoreceptor cell synapses which communicate with bipolar and horizontal cell
dendrites and (2) the inner plexiform layer containing bipolar cell and amacrine cell
synapses to ganglion cells. Neurotransmitters, including glutamate, γ-aminobutyrate,
glycine, acetylcholine, dopamine, and serotonin, are responsible for the signaling across
the synapses. The Müller glial cells and retinal vasculature maintain retinal homeostasis
by ensuring an adequate nutrient supply and eliminating waste.
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Retinal Vasculature and Pericytes
The blood supply to the retina is carried by the central retinal artery, the choroidal blood
vessels, and their associated capillaries. These vessels provide oxygen while removing
waste throughout the retina. Blood vessels throughout the body are lined with
endothelial cells coated with pericyte cells, which forms the blood-retina barrier. The
pericyte cells wrap around the endothelial cells of capillaries to provide stability, by
maintaining the blood-retinal barrier, and by regulating blood flow (Jo et al. 2013,
Peppiatt et al. 2006).

The Müller Glial Cells
The Müller glial cells are the principal glia in the retina. Müller glial cells support
surrounding cells through the release of growth factors and antioxidants, and uptake of
extracellular debris. Thus, functional changes in Müller glial cells can impact both
neuronal and vascular cells in the retina. The anatomical localization of these cells
throughout the retina allows for the maintenance of homeostasis, as well as providing
structural and metabolic support to all cell types. The somata of Müller cells reside
between either plexiform layer. Trunks extend from the somata in each direction,
allowing Müller cells to span the width of the retina. Müller cells assist in the uptake and
metabolism of retinal neurotransmitters. Regulation of neurotransmitters by Müller glial
cells within the synapse prevents the inappropriate activation of neurons. Furthermore,
the Müller cells support and maintain the blood-retinal barrier (Shen et al. 2012).
Transgenic mice with conditional Müller glial cell dysfunction exhibited accelerated
photoreceptor apoptosis, and blood-retinal barrier breakdown, resulting from weakened
4

tight junctions between endothelial cells (Shen et al. 2012). These observations
substantiate the neural and vascular protective functions of the Müller cells.

Examination of the Retina
Imaging of the fundus (back of the eye) allows for visual inspection of the retina and
macula, as well as the choroid and blood vessels. The majority of fundus examinations
are conducted using a fundus camera, ophthalmoscope. These fundus images are
principle for the determination of DR. In a healthy retina the macula, is devoid of blood
vessels while in a diseased retina, the vasculature show signs of venular bulging and/or
retinal thinning (Jonsson et al. 2016).

Diabetic Retinopathy
DR is the most common complication associated with diabetes, and it is the leading
cause of blindness in the United States (CDC 2008). The early stages of DR are
typically asymptomatic, despite the underlying cellular and metabolic changes because
there are no physically perceivable changes to vision (Wilkenson et al. 2003). These
early stages are collectively referred to as the non-proliferative stage, which is
characterized by microaneurysms, hemorrhages, exudates, and cotton-wool spots;
which are indicative of nerve fiber damage. Notably, angiogenic changes do not develop
during this early stage (Nayak et al. 2007). The development of retinal abnormalities is
monitored by fundus imaging during yearly eye exams. The asymptomatic phase of DR
is accompanied by retinal cell death, vascular swelling, and vascular leakage.
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Diabetic patients with DR become aware of their disease when they progress to the
proliferative diabetic retinopathy (PDR) stage, and visual changes are apparent. The
progression of PDR is associated with pathological retinal angiogenesis. The
symptoms in this final stage initially begin with spotty vision and ultimately lead to
blindness. These symptoms are caused by the inappropriate growth of weak blood
vessels that can easily rupture. The spots in the field of vision occur with the leakage of
blood from these weak vessels, as well as by excessive inflammation. The
angiogenesis and inflammation in DR is associated with a number of different factors.
Intracellular adhesion molecule-1 (ICAM-1) and vascular endothelial growth factor
(VEGF) are two factors that have been implicated as playing a role in detrimental
cellular changes within the retina.

Cellular Changes in Diabetic Retinopathy
Many cell types undergo functional alterations in the progression of DR. These
changes denote the progression and the severity of the disease. Pericyte cell loss, due
to an increase in oxidative stress, is the first histopathological change in the
development of DR (Amano et al. 2005). Pericyte loss promotes the hyperdilation of
endothelial cells, and early vascular abnormalities. The degeneration of the retinal
neuronal cells has also been purported to coincide with the inability of the vasculature to
remove waste, and a change in function of the Müller glial cells (Frydkjaer-Olsen et al.
2015). The Müller cells have, as well, been shown to shift from a primarily antiinflammatory state to a pro-inflammatory state in the progression of DR (Gerhardinger
6

et al. 2005, Harada et al. 2006, Zong et al. 2010). Analysis of gene expression in Müller
cells isolated from retinae of streptozotocin (STZ)-diabetic rats revealed an upregulation of inflammatory-associated proteins (Gerhardinger et al. 2005). Thus, the
biochemical and molecular changes that occur in Müller glial cells disrupt their function
and result in vascular and neuronal cell dysfunction and death.

Molecular Mechanisms of Diabetic Retinopathy
Oxidative Stress
At the molecular level, multiple pathways are involved in the pathological changes that
occur during DR. However, many of these are not fully understood. Figure 1 illustrates
pathways that have been associated with the overproduction of reactive oxygen species
(ROS) leading to DR. These include mitochondrial dysfunction, the activation of PKC,
and the production of AGEs (Kanwar et al. 2009, Wu and Juurlink 2002, Xia et al.
1994). Additionally, there is decreased antioxidant function further promoting the
development of oxidative stress (Kanwar et al. 2009). The increased level of oxidative
stress further activates intracellular signaling pathways. In STZ diabetic rats, treatment
with antioxidants, including, astaxanthin and curcumin, have been shown to alleviate the
increased leukostasis, which may result from elevated levels of ICAM-1, and the
induction of increased VEGF synthesis (Yeh et al. 2016, Obrosova et al. 2001). The
combination of excessive ROS generation and antioxidant depletion are key factors in
the development of DR.
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Figure 1: Proposed Pathways Involved in the Development of DR
The depiction of pathways involved in the progression of DR. Early metabolic
and antioxidant mitochondrial dysfunction induced by high glucose inhibits the
metabolism of glucose as a result of reduced enzymatic activity of GAPDH. The
build up of metabolites promotes the development of ROS through both the PKC
and AGE-RAGE pathway. The development of oxidative stress has been shown
to promote the inappropriate activation of NF-B leading to the excess synthesis
of ICAM-1 and VEGF.
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Mitochondrial Dysfunction
Mitochondria are the primary source of ROS in the cell, and mitochondrial dysfunction is
thought to be the initial source of oxidative changes that occur in DR (Trudeau et al.
2006). Trudeau et al. observed early structural and functional changes of mitochondria
in rat retinal endothelial cells grown in high glucose medium (30 mM), in comparison to
those cultured in low glucose medium (Trudeau et al. 2006). After 30 minutes of
exposure to high glucose conditions, the mitochondria of the rat retinal endothelial cells
exhibited fragmented membranes. Mitochondrial membranes structure recovered to
normal within two hours of high glucose treatment (Trudeau et al. 2006). However,
when rat retinal endothelial cells were cultured in high glucose for a minimum of 48
hours, mitochondrial fragmentation continued for the remainder of the 6-day analysis.
Additionally, when rat retinal endothelial cells were cultured in high glucose for three or
six days, there was a significant reduction in oxygen consumption and an increase in
the release of cytochrome c indicating a change in mitochondrial metabolism (Trudeau
et al. 2006). These changes in mitochondrial function caused deregulation of many
cellular systems due to a reduction in ATP synthesis and increased production of ROS.

In addition to impaired mitochondrial function, the increase production of ROS by the
mitochondria impairs glucose metabolism, resulting from a reduction in the enzymatic
function of glyceraldehyde-3-phosphate (GAPDH). The impaired enzymatic function of
GAPDH has been linked to dysfunction in antioxidant mechanisms (Kanwar et al. 2009).
In retinal endothelial cells maintained under hyperglycemic conditions, mitochondrial
superoxide dismutase, an enzyme known to scavenge ROS, is diminished (Kowluru et
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al. 2006). Furthermore, under hyperglycemic conditions, overexpression of
mitochondrial superoxide dismutase restored GAPDH function (Xueliang et al. 2003).
The inhibition of GADPH, as observed in diabetes, leads to the build-up of glucose
metabolites, including glyceraldehyde 3-phosphate. The accumulation of high
concentrations of these glucose metabolites promotes further downstream activation of
pathways including the PKC and AGE-RAGE pathway (Figure 1). Increased activation
of these signaling cascades further promotes an increase in oxidative stress.

ROS Activation of Intracellular Signaling
Collectively, the development of oxidative stress results in the activation of pathways
involved in inflammation and angiogenesis primarily through activation of nuclear factorB (NF-B) (Soufi et al. 2012). Indeed, the activation of NF-B is considered an
important step in the progression of DR (Nagai et al. 2007, Zhao et al. 2012, Romeo et
al. 2002, Zheng et al. 2004), specifically due to its regulation of ICAM-1 and VEGF
(Mamputu et al. 2004, Shelton et al. 2007 Cervellati et al. 2014). ICAM-1 is an
important adhesion molecule involved in the inflammatory response associated with DR
(Mamputu et al. 2004, Joussen et al. 2001). During normal function, ICAM-1 functions
to facilitate leukocyte transmigration by allowing attachment and migration of leukocytes
through blood vessels. However, when produced in excess, ICAM-1 leads to an
inordinate degree of leukostasis, which was observed in a STZ-induced diabetic rat
model of DR (Tang et al. 2013). This increase in leukocyte adhesion correlated with
increased endothelial cell apoptosis (Joussen et al. 2001). The accelerated loss of
endothelial cells alters the structure of the vasculature, resulting in leakage and the
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rupture of blood vessels and, thus, impairing the adequate blood flow within the
vasculature (Joussen et al. 2001).

With the impaired vascular function, the reduced blood flow to the retina promotes an
ischemic environment. To enable restoration of appropriate tissue oxygen
concentrations, angiogenesis is stimulated. Normally, angiogenesis is important for
improved blood flow in areas where the vasculature is damaged. However, in DR,
overproduction of VEGF leads to excess growth of these blood vessels, which impedes
vision. Vision loss occurs as a result of vessel growth and leakage of blood near the
macula. Also, irreversible vision loss takes place after extensive blood vessel growth
promotes the formation of a fibrovascular membrane (FVM). The surgical removal of
FVMs is frequently required to prevent retinal detachment and permanent loss of vision
(Kim et al. 2015).

Treatment of Diabetic Retinopathy
Therapeutic options for diabetic patients with DR depends on how pronounced their
retinal abnormalities are. During the early stages of DR, the treatment includes
continued control of diet and blood pressure (Liu et al. 2013). As DR progresses,
therapies are directed at inhibiting the inappropriate growth of blood vessel. These
treatments are monoclonal antibodies designed to neutralize VEGF and thus are
referred to as anti-VEGF therapy (Yang et al. 2013). Individuals with PDR that abstain
from treatment will progress to severe vision loss and eventually become blind.
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Currently, anti-VEGF therapies are the gold standard of treatment for DR. Although,
photocoagulation therapy is often used in conjunction with the anti-VEGF therapies.
This treatment regimen employs a high-intensity laser to seal or destroy damaged and
leaking vessels in the retina (Yang et al. 2013). If these steps are performed before
retinal damage, the reversal of vision loss is likely (Yang et al. 2013).

Current treatment strategies for patients with DR reduce vision loss. However,
significant side effects are associated with their use. Some common side effects of
therapies for DR include scotoma (blind spot), retinal scarring, macular edema, and/or
vitreous hemorrhage (Sher et al. 2013, Shin et al. 2009). In addition to these side
effects, the therapeutic effects of these treatments diminish in a short period of time.
One study showed improvement of visual acuity in 17 patients treated with intravitreal
bevacizumab, an antibody against VEGF. However, visual acuity declined to baseline
by three months following treatment, indicating a need for repeated treatments (Preti et
al. 2012). Targeting the VEGF signaling cascade is just one of many plausible
therapeutic options for control of DR. Another possible therapeutic would include
targeting upstream molecules which may have equal or greater beneficial effects. One
such target that has gained interest is modification of the transcriptional activity of NFB, a transcription factor that has been shown to play a role in the progression of DR
(Nagei et al. 2007, Soufi et al. 2012).
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NF-κB’s Role in Diabetic Retinopathy
NF-B activation is an important factor in the progression of DR, because of its
regulatory effects on proteins involved in inflammation and retinal angiogenesis (Figure
1). NF-B also plays a beneficial role in many other cellular processes, including
inflammation, immunity, cell proliferation, differentiation, and survival. This diverse
functionality of NF-B is a result of extensive various subunits and methods of
activation. The need for diverse NF-B function is due to variability amongst cell types,
differences in phosphorylation, and other post-translational modifications (Romeo et al.
2002, Werner et al. 2005, Brown et al. 1994).

Generally, NF-B is maintained in the cytoplasm when dimerized by IB. Once NF-B
is activated, at least 150 genes have been reported to be under the transcriptional
regulation of NF-B (Ghose and Bhattacharyya 2015). Three pathways are involved in
the activation of NF-B, including the canonical, non-canonical, and ROS-activated. In
DR, the overproduction of ROS promotes the inappropriate and over activation of NFB. Regulation of NF-B activity may provide a therapeutic target for DR. Previous
studies show that inhibition or reduced activation of NF-κB slows the progression of DR.
Nagei et al. (2007) inhibited NF-κB in a STZ diabetic mouse model of DR with
dehydroxymethylepoxyquinomicin, reducing inflammation and slowing progression of
DR compared to vehicle treatment only groups (Nagai et al. 2007). However, due to the
vast role of NF-B in regulating cellular function, long-term inhibition may not be
beneficial.
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In a similar study, Soufi et al. treated STZ diabetic mice with resveratrol, a plant-based
antioxidant compound (Soufi et al. 2012). Resveratrol treatment resulted in decreased
NF-κB activation, as measured by antibody binding of the p65 subunit in nuclear
extracts (Soufi et al. 2012). Furthermore, the treatment reduced apoptosis and
inflammation (Soufi et al. 2012). These changes likely occur as a result of attenuating
oxidative stress. Thus, attenuation of NF-B activation by ameliorating hyperglycemia
induction of oxidative stress may present an alternative therapeutic target for the
treatment of DR.

Photobiomodulation
Photobiomodulation
A potential alternative therapy for DR includes treatment with far-red to near-infrared
(NIR) light (630 nm-1000 nm). This light treatment has been shown to cause a
biological change including mitigation of oxidative stress, repair of mitochondrial
function, and prevent cell death, and is, thus, commonly referred to as
photobiomodulation (PBM) (Ball et al. 2011). Treatment with low-energy lasers or lightemitting diode (LED) arrays has been reported to be beneficial in models of tissue repair
and wound healing (Gaida et al. 2004, Gupta et al. 2015, Pinto et al. 2009). In a model
of wound healing, Sprague-Dawley rats treated with 904 nm light had a higher healing
efficacy on the induced burn wounds compared to treatment with sulfadiazine cream, a
common burn therapy (Gupta et al. 2015). Furthermore, PBM has shown promise in
clinical trials for the treatment of mucositis and stroke. 670 nm light reduced the
incidence of mucositis in the treatment patients undergoing a bone marrow transplant
14

(Hodgson et al. 2012, Whelan et al. 2002). In clinical trials of PBM in stroke patients,
light therapy has shown promise in both safety and improved outcomes (Zivin et al.
2009, Lampl et al. 2007). Taken together, studies involving PBM have shown beneficial
effects in the disease models chosen. Understanding treatment with far-red to NIR
light, though, remains challenging due to varying effects observed between wavelengths
and dosage. For example, rats with burn wounds received treatment with 670 nm light
at a range of dosages (1, 5, 9, and 19 J/cm2) or received sham treatment for either
three or five days a week. Animals which received treatment with 670 nm light at a
dosage of 1 J/cm2 had a significantly higher rate of healing than rats treated with the
various other dosages, as well as rats which received sham treatment (Al-Watban and
Delgado 2005). Additionally, the wavelength selected for treatment has differential
effects. Comparative analysis of treatment with 665, 730, 810, and 980 nm light (36
J/cm2) was performed in a mouse model of traumatic brain injury (TBI) (Wu et al. 2012).
TBI was induced in adult male BALB/c mice by the controlled drop of a weight onto their
skull. Animals received a single dose of their respective treatment fours-hours post-TBI
(Wu et al. 2012). Mice performed various tasks for measurement of neurological injury
from post-injury day 0 to postinjury day 30 (Wu et al. 2012). Animals treated with 665
and 810 nm light post-injury had a significant improvement in neurological function in
comparison to TBI control animals (Wu et al. 2012). However, there was no significant
difference in neurological function between animals treated with 730 nm or 980 nm light,
compared to animals which were sham treated (Wu et al. 2012). Therefore,
understanding treatment with light in the far-red to NIR range remains challenging due
to varying effects observed between wavelengths and dosage. The beneficial effects of
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treatment with light in the far-red to NIR range reported thus far, support further
investigation into optimal dosages and wavelengths.

Photobiomodulation in Models of Oxidative Stress
Beyond the alleviation of symptoms, another therapeutic effect observed after treatment
with PBM is the diminution of oxidative stress. In a number of models, of which oxidative
stress has pathological significance, treatment with far-red to NIR light has been shown
to reduce oxidative stress and alleviate symptoms and or pathological markers of the
disorder (Tang et al. 2013, Saliba et al. 2015, Silva Macedo et al. 2015, Purushothuham
et al. 2014). In cell culture models of oxidative stress, PBM was able to diminish ROS.
ARPE-19 cells, immortalized retinal pigment epithelial cells, and human primary retinal
pigment epithelial cells treated with hydrogen peroxide showed diminished ROS when
treated with 670 nm light. The authors report that although ROS is diminished, it was
not to a sufficient level to preserve mitochondrial membrane potential and reduce cell
death (Fuma et al. 2015). Similarly, a reduction in both NO and ROS was observed in
dental pulp cells treated with LPS and 855 nm light (Montoro et al. 2014).

Similar results were observed in vivo. Male 2-month-old Wistar rats were exposed to
formaldehyde (1%, 90 in), as a model of acute lung inflammation, and treatment with
660 nm light decreased oxidative stress while simultaneously increasing the presence
of antioxidants in comparison to non-treated rodents exposed to formaldehyde (Silva
Macedo et al. 2016). Furthermore, in two different mouse models of Alzheimer’s
disease five month K3 mice and seven month APP/PSI mice were treated for 90
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seconds with 670 nm light for five days per week over a four-week period, which
resulted in reduced lesion size in comparison to non-treated Alzheimer’s mice
(Purushothuham et al. 2014). Corresponding to these reductions in pathological
markers was a decrease in the presence of 8-hydroxy-2’-deoxyguanosine, a marker of
deoxyribonucleic acid (DNA) oxidative damage (Purushothuham et al. 2014). These
studies are just a few examples demonstrating the effects of PBM on oxidative stress
and disease manifestations.

Photobiomodulation in Retinal Disorders
Several studies using 670 nm light on retinopathies have demonstrated therapeutic
effects for this treatment. For example, in Long Evans rats treatment with 670 nm LED
has been used to protect against the toxic effects of methanol (Eells et al. 2003).
Methanol exposure leads to formic acid production and metabolic acidosis resulting in
injury to the retina and optics nerve as observed through abnormal ERGs. Additionally,
methanol treatment leads to histological abnormalities including retinal swelling and
disruption of the mitochondria in photoreceptors (Eells et al. 2003). These symptomatic
and histological changes observed in methanol-intoxicated rodents were significantly
reduced in animals treated with 670 nm light for 144 seconds at a dosage of 4.5 J/cm 2,
at 5, 24, and 50 hours after intoxication (Eells et al. 2003). In a rodent model of retinitis
pigmentosa, treatment with 670 nm light also regulates cytoprotection and reduces the
loss of photoreceptors (Machida et al. 2013). Furthermore, retinal function was
improved in animals treated with 670 nm light compared to control (Kirk et al. 2013).
Treatment with 670 nm light also promotes improvements in visual acuity in age-related
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macular degeneration (AMD) (Merry et al. 2013). In a small patient sample, nine
individuals with AMD received treatment with 670 nm light at 50-80 W/cm2, 4-7.68
J/cm2, and a duration of 88 +/- 8 seconds three times per week for six weeks. Patients
treated with 670 nm light had a significant improvement in visual acuity, when compared
to measures of visual acuity collected prior to treatment (Merry et al. 2013).

Photobiomodulation in Models of Diabetic Retinopathy
Collectively, previous studies show that PBM attenuates oxidative stress and
ameliorates disease manifestations in retinal disorders. It is, therefore, likely that PBM
may be beneficial for the treatment of DR. 670 nm light treatment of retinal ganglion
cells, Muller glial cells and RPE cells cultured in high glucose concentrations to simulate
diabetes reduced superoxide production and cell injury (Tang et al. 2013). In the STZ
rat model of DR, 670 nm light treatment at the onset of diabetes, significantly reduced
the development of lesions, leukostasis, and reduced the increase in ICAM -1 synthesis
associated with disease (Tang et al. 2013). Similar observations were made in the STZmouse model of DR (Saliba et al. 2015). Additionally, Saliba et al. reported that 670 nm
light treatment of advanced stage diabetes in rodents also slowed disease progression
(Saliba et al. 2015). A recent series of case reports also provides clinical evidence that
670 nm light reduces retinal edema associated with diabetes (Tang et al. 2015). Beyond
these findings, little is known about the intracellular effects of PBM in models of DR;
however, work in other areas has helped provide insight behind the mechanism of
action for PBM.
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Mechanism of Action of PBM
Therapeutically beneficial effects of PBM have been observed in a number of disorders
such as Alzheimer’s disease, wound healing, and various retinal diseases
(Purushothuham et al. 2014, Gupta et al. 2015, Eells et al. 2003, Tang et al. 2013). The
improved functional outcomes and diminution of disease causing lesions have been
found to coincide with an improvement in mitochondrial function (Cummins et al. 2013).
Mitochondrial dysfunction is an early step in the development of an assortment of
disorders, particularly in the retina, a mitochondrial rich environment (Trudeau et al.
2006, Marshall et al. 2015, Maleki et al. 2013). Photobiomodulation has been shown in
several studies to modulate mitochondrial function (Agrawal et al. 2014, Cummins et al.
2013, Wong-Riley et al. 2005). In a rodent model of optic nerve injury, mice were either
sham treated or treated with 670 nm LED (88 seconds, 60 mW/cm2, 5 J/cm2), for one or
seven days after injury. Sham-treated mice with optic nerve injury presented with a
change in mitochondrial structure and activity, as determined by transmission electron
microscopy. The changes to the mitochondrial structure in the model of optic nerve
injury were attenuated in the injured mice receiving 670 nm light (Cummins et al. 2013).
The effects of NIR light on mitochondrial function has been hypothesized to induce
functional changes in the mitochondrial photoacceptor molecule, cytochrome c oxidase
(CcO). In cultured primary neurons, treatment with 670 nm light significantly increased
the activation of CcO leading to improved mitochondrial function as indicated by an
increase in ATP synthesis (Wong-Riley et al. 2005, Agrawal et al. 2014). Furthermore,
treatment of primary neurons with 670 nm light protected from induced cell death by
potassium cyanide, an inhibitor of CcO (Wong-Riley et al. 2005). Recent studies have
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shown that NIR irradiation results in redox alterations in the CcO complex activating
intracellular signaling cascades which culminates in improved mitochondrial function
and increased synthesis of cytoprotective factors (Ball et al. 2011, Demontis et al.
2002). Beyond these findings, due to the prolonged effect of brief treatment with light in
the far-red to NIR range, it is likely that PBM induces a cascade of events leading to the
stimulation of gene expression, protein synthesis, and oxidative metabolism. Although
the mechanism has not been fully elucidated, it has been postulated that the light
photons modify the structure of CcO, improving electron transport and increasing ATP
production (Lohr et al. 2009). Also, it has been observed that light treatment culminates
in the release of a small burst of ROS or nitric oxide (NO) and activation of transcription
factors which modulate gene transcription (Lohr et al. 2009, Zhang et al. 2009).
Naturally, CcO can bind either oxygen or NO on the heme of iron or copper center. As
suggested by Lohr et al. a NIR photon photodissociates NO from CcO of mitochondria
with abnormal function. The release of NO promotes oxygen to bind CcO and reestablish mitochondrial function. This release of NO is referred to as the burst, and may
promote transcription (Figure 2). In regards to mitochondrial associated genes, gene
transcriptional changes after light treatment result in the upregulation of cytoprotective
cytokines, as previously mentioned, and antioxidants such as mitochondrial superoxide
dismutase (Agrawal et al. 2014, Huang et al. 2013, Zhang et al. 2003, Tang et al. 2013).

Additionally, treatment with light in the NIR spectrum has been found to increase the
expression of CcO in an animal model of AMD (Begum et al. 2013). In the complement
factor H knockout (CHF -/-) mouse model of AMD, animals were exposed to 670 nm
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LED for 6 minutes twice a day (Begum et al. 2013). This NIR treatment was continued
for 14 days. The CHF -/- mice exposed to light treatment had a significant increase in
CcO as measured by immunostaining in sectioned eyes in comparison to those
collected from sham-treated CHF-/- animals (Begum et al. 2013). Collectively, these
studies further provide evidence that treatment with PBM promotes improvement to
mitochondrial activity through changes in mitochondrial-associated gene regulation
(Begum et al. 2013).

Microarray analysis was used to elucidate additional pathways and cellular changes that
occur after treatment with PBM. Gene expression profiles performed on treated human
fibroblasts indicate that PBM regulates 111 genes. The genes regulated by PBM
include those involved in cell proliferation, suppression of apoptosis, cell growth, redox
regulation, and mitochondrial energy metabolism (Song et al. 2003). While CcO is a
likely photoacceptor molecule, other downstream transcriptional changes occur which
may or may not result from CcO activation. Therefore, additional research is needed to
determine PBM mechanism.
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Figure 2: Image Depicting the Theorized Effects of PBM on CcO
Work by Lohr et al. (2009) and Zhang et al. (2009) suggests that in a state of
mitochondrial dysfunction CcO preferentially binds NO over oxygen. Treatment
with NIR light photodissociates NO, therefore allowing oxygen to bind. This
binding of oxygen promotes improvement to mitochondrial function and sub
sequentially induces changes in activation of transcription factors and gene
transcription. ( represents a change)
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Effects of Photobiomodulation on NF-B
In a small assortment of models, PBM has been found to modulate the activation of the
transcription factor NF-B. In a rodent model of burn healing, animals treated with 904
nm (0.2 J/cm2) light for either 4 or 7 days post injury exhibited a decrease in NF-B
translocation to the nucleus (Gupta et al. 2015). Although this is not a direct measure of
transcriptional activity, it is indicative of a reduction in the activation of NF-B.
Interestingly, differential observations were reported by Mafra de Lima et al. (2009) in
regards to the effects of far-red to NIR light treatment on the activity of NF-B. Bronchi
from Wistar rats were dissected and treated with 655 nm at a dose of 2.6 J/cm 2 (Mafra
de Lima et al. 2009). After treatment, relaxation of bronchi smooth muscles was
restored. When an NF-B antagonist was introduced, these effects were blocked.
Therefore, in this model, NF-B activation by 655 nm is preferential (Mafra de Lima et
al. 2009). Outside of these studies, little is known about the effects PBM has on NF-B
activity in additional models or with regard to other treatment protocols. The varying
effects of PBM on NF-B activity could be due to the dual role of NF-B, for eliciting
either a pro-inflammatory or anti-inflammatory response, or differences between cell
type studies and the manner in which NF-B was activated (Liu et al. 2007, Fong et al.
2008). These conflicting results highlight a need for additional research to understand
the effect of PBM on NF-B transcriptional activity. Analyzing the effects of PBM on NFB in a model of DR may help clarify inconsistencies.
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Summary and Gap in Knowledge
The progression of DR has been linked to increased activity of NF-B, as well as
increased levels of ICAM-1 and VEGF (Mamputu et al. 2004, Lennikov et al. 2004). It is
well established that NF-B activation occurs in response to elevated ROS (Kowluru et
al. 2003, Kowluru et al. 2007, Wautier et al. 1994). Furthermore, 670 nm light has been
shown to inhibit oxidative stress associated with pathological changes in the
development of DR. Tang et al. confirmed that the inhibition of oxidative stress was
correlated with a decrease in ICAM-1 levels and leukostasis (Tang et al. 2013). Beyond
this work, little is known about changes in intracellular signaling and transcriptional
activity. Research by Gupta et al. and Mafra et al. investigated the effects of PBM on
NF-B activity, however, the observed changes in NF-B activity were dependent on
the models analyzed (Gupta et al. 2015, Mafra de Lima et al. 2009). PBM modulation of
signaling in the retina has yet to be elucidated. We have conducted studies to
characterize the mechanisms by which 670 nm light affects retinal signaling pathways in
a cultured cell model of DR. These studies examine the effects of 670 nm light on
activation of NF-B and cellular level of ICAM-1 and VEGF in a Muller glial cell model of
DR.

To perform these studies, Müller glial cells were cultured in either normal or high
glucose to replicate normoglycemic and hyperglycemic conditions. Groups from each
culture condition received either 670 nm LED treatment at a dosage of 4.5 J/cm 2 or
sham treatment. These conditions allowed for analysis of hyperglycemic conditions in
the selected model, as well as determine the therapeutic effects of 670 nm LED
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treatment on attenuation of hyperglycemic-induced differences. The Müller glial cell
model was selected because of their principle role of maintaining homeostasis for both
the vasculature and for neuronal cells. Thus, the ability to modulate hyperglycemicinduced changes in Müller glial cells may be biologically important for ameliorating
changes in additional cell types.

II.

HYPOTHESIS AND SPECIFIC AIMS

DR is the leading cause of blindness in the United States and accounts for 10,000 new
cases annually. The early stages of disease are asymptomatic despite the induction of
mitochondrial dysfunction, increased AGE-RAGE interaction, and excess activation of
PKC pathways, resulting in an increase in oxidative stress. This, in turn, leads to
increased inflammation and retinal neovascularization, due in part to the activation of
NF-κB (Mamputu et al. 2004, Shelton et al. 2007). Two of the proteins regulated by NFB and involved in inflammation and retinal neovascularization, ICAM-1 and VEGF, are
implicated in the progression of DR and loss of vision.

Intraocular injections of anti-VEGF agents is the current therapy for DR; however, this
approach is invasive and subject to undesirable side effects (Yang et al. 2003). PBM
using 670 nm LED arrays is currently under investigation as a potential therapeutic
option. Tang and colleagues have shown that 670 nm light attenuates DR in an
experimental rat model of DR and in patients with diabetic non-center edema (Tang et
al. 2013, Tang et al. 2015, Saliba et al. 2015). In the STZ-diabetic rodent model of DR,
an observable reduction in leukostasis, which correlated with the reduction in ICAM-1
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was also observed when animals were treated with 670 nm LED (Tang et al. 2013).
Additionally, these observations corresponded to a reduction in oxidative stress. Based
on the relationship between the induction of oxidative stress and the increase activation
of NF-κB, as well as the relationship between increased activity of NF-κB and levels of
ICAM-1 and VEGF in DR, we predict that PBM will reduce NF-κB activity and reduce
the relative level of ICAM-1 and concentration of VEGF. Therefore, we hypothesize that
in an in vitro model of DR, PBM will reduce the activity of NF-κB, and reduce the level of
ICAM-1 and concentration of VEGF. Characterization of the effects of PBM on NF-κB
activity and changes in the level of ICAM-1 or VEGF will advance our understanding of
the mechanism of action of PBM. Mechanistic studies are essential to move this
treatment modality into the clinic for treatment of DR. We plan to test this hypothesis
with the following specific aims:

Specific Aim 1: Determine the effects of PBM on the activity of NF-κB.
Working Hypothesis: PBM will reduce activation of NF-κB in a model of DR.

Specific Aim 2: Determine the effects of PBM on the levels of VEGF and ICAM-1.
Working Hypothesis: PBM will reduce the concentration of VEGF and the level of
ICAM-1 in a model of DR.
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III.

MATERIALS AND METHODS

Cell Line
Müller glial cells are in direct contact with multiple cell types in the retina and are
important for the maintenance of homeostasis. Prior research analyzed changes in
Müller glial cells cultured under hyperglycemic conditions. High glucose culture
conditions resulted in an increase in transcriptional activity of NF-B (Shelton et al.
2009). It has also been observed that under hyperglycemic conditions Müller glial cell
production ICAM-1 and VEGF and ICAM-1 is increased (Bai et al. 2009, Shelton et al.
2007). Thus, Müller glial cells develop abnormalities consistent with those observed in
DR, and this model will facilitate the analysis of the actions of PBM on intracellular
signaling systems. Because we are using a cell culture model, we can examine
signaling within one cell type. However, because we are using an isolated cell culture
system, signaling which naturally occurs between cell types cannot be examined and
will require further work in an animal model. For the scope of this study, an isolated cell
culture system is ideal to better understand intracellular signaling activated by 670 nm
light.

Culture Conditions
Immortalized rat Müller glial cells (rMC) were obtained from John Mieyal at Case
Western Reserve University. Stock cells were maintained in a solution of 10% DMSO in
10% FBS with Dulbecco’s Modified Eagle’s Medium (DMEM) and stored in liquid
nitrogen. For tissue culture experiments, cells were suspended in DMEM with 1%
penicillin-streptomycin, 10% heat-inactivated fetal bovine serum (HI-FBS), and 110
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mg/L sodium pyruvate. For light treatment experiments, cells were cultured for up to six
days in either high (25mM) or normal (5 mM) glucose with 1% penicillin-streptomycin,
2% HI-FBS and 110 mg/mL sodium pyruvate. Media was replaced daily, or twice daily
for transfected cells to maintain stable glucose concentrations. As shown in Table 1
samples collected on the last day of treatment indicate that levels of glucose were
maintained for cells cultured in 100 mm dishes. However, for cells cultured in a six-well
dish culture glucose levels were not maintained for the full 24 hours. Therefore media
was changed every 12 hours to retain stable glucose concentrations (Table 2). Cultures
were stored in a 37°C incubator with 5% CO2. For six well or 100 mm plates, 20,000
cells/well or 80,000 cells/100 mm dish were plated, respectively.

Table 1: Glucose Levels After 24 Hours of Incubation
Sample

Calculated Glucose Concentration

Normal Glucose (stock media)

1.86 mg/mL

High Glucose (stock medial)

5.78 mg/mL

Normal Glucose (100mm dish)

1.53 mg/mL

High Glucose (100 mm dish)

6.12 mg/mL

Normal Glucose (6 well plate)

0.54 mg/mL

High Glucose (6 well plate)

5.93 mg/mL
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Table 2: Low Glucose Levels After 12 Hours of Incubation
Sample

Calculated Glucose Concentration

Normal Glucose (Control)

1.75 mg/mL

Normal Glucose (6 well dish)

1.43 mg/mL

670 nm light Treatment
Cultures were treated once daily between 11:00 – 12:00 pm. Cells cultured in high or
low glucose were placed on the surface of the 670 nm 75 cm 2 LED array (Spectralife,
QDI, Barneveld, WI) (Table 3). PBM treatment consisted of 670 nm irradiation for 180
seconds at a power intensity of 25mW/cm2, resulting in an energy density of 4.5
Joules/cm2 (0.025 W/cm2 x 180 sec = 4.5 J/cm2). Sham-treated cells were handled in a
similar manner, except the LED device was not turned on. Cells were either light- or
sham-treated for three days (NF-B assessment) or 5 days (ICAM-1 and VEGF
assessment) depending on assay protocol. Following treatment, conditioned media
and/or cell lysates were collected and stored at -80°C for future processing.

Table 3: Summary of Treatment Regimen for Experimental Groups
Group
1
2
3
4

Media
High Glucose
(FBS+25mM Glucose)
High Glucose
(FBS+25mM Glucose)
Normal Glucose
(FBS+5mM Glucose)
Normal Glucose
(FBS+5mM Glucose)
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Treatment
Light
Sham
Light
Sham

Plasmid Growth and Purification
DH5 α bacterial cells, containing NF-B or Renilla plasmids, were obtained from John
Mieyal at Case Western Reserve University. To initiate a starter culture, stabs from
frozen stock cultures (maintained in 20% glycerol) were incubated in lysogeny broth
(LB) containing 100 μg/mL ampicillin. A starter culture (5mL) was incubated overnight
at 37°C shaking at 300 rpm. After initial incubation, the starter culture was added to 250
mL of LB broth containing 100 μg/mL ampicillin and allowed to shake at 300 rpm
overnight at 37°C. The following DNA purification steps were performed utilizing a
Maxi-prep kit from Qiagen and performed per manufacturer instructions. Transfection of
the plasmids was confirmed by gene sequencing, which was performed by Angela
Schmoldt at the School of Freshwater Science, University of Wisconsin-Milwaukee.
Forward and reverse primers were designed for sequencing of both the NF-B and
Renilla plasmid. Table 4 shows the designed primer sequences for amplification of the
transfected plasmids. BLAST was used for the comparison and confirmation of
transfection.

Table 4: Primers Used for Gene Sequencing
Plasmid Primer

Sequence

NF-B forward primer

5'CACCTCCCCC TGAACCTGAA AC3'

NF-B reverse primer

5’CCTCTAGAGGATAGAATGGC3’

Renilla forward primer

5’CGAATTCGAACACGCAGATG3’

Renilla reverse primer

5’CTGCATTCAGTTGTGGTTTG3’
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Transfection of Müller glial cells with Luciferase and Renilla Plasmids
To transfect Müller glial cells, 20,000 cells/well were plated in a six-well dish. After
three days in culture, cells were approximately at a confluence of 60-70%. Cells were
washed twice with 1x phosphate buffered saline (PBS). They were then co-transfected
with a NF-B and Renilla plasmid. Transfection was performed with a cocktail
containing 1 mL/well Opti-MEM, 5 μL/well lipofectamine, 1 μg/well NF-B plasmid and
0.1 μg/well Renilla plasmid (Shelton et al. 2007). Transfection was allowed to proceed
for 8 hours. Following transfection, the transfection cocktail was aspirated and replaced
with DMEM, 5 mM glucose, 2% FBS, 1 % penicillin-streptomycin, 110 mg/L sodium
pyruvate for 3-4 hours. Media was again aspirated and replaced with appropriate
culture media, high (25 mM) or normal (5 mM) glucose. Cells were maintained in either
high or normal glucose conditions for three days and were either treated with 670 nm
light or sham treated for 180 seconds daily. At the completion of the treatment, lysates
were collected in 1x passive lysis buffer and stored at -80°C until further analysis.

Measurement of NF-B Transcriptional Activity
A Biotek Synergy HT plate reader was used for detection of luminescence. Luciferase
readouts were normalized to Renilla readings. The Renilla sequence provides an
internal control because it is constitutively expressed, and not affected by the treatment.
If transfection does not occur equally between groups, the Renilla luminescence
provides a method for the normalization of data.
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Cell Collection and Lysate Processing for ICAM-1 analysis
For cell collection, plates were first washed with 1X PBS and cells were then detached
with trypsin. Trypsinization was stopped by adding 8 mL of growth media to the 100
mm plate. Next, cells were centrifuged at 1,000 x g for 5 minutes. The pellet was
washed with 1 mL of 1X PBS and centrifuged at 1,000 x g for 5 minutes. Lysis was
performed on ice for 20 minutes in 100 µl of 1X RIPA buffer and 1X protease inhibitor
cocktail (Thermo Scientific) at a dilution of 1:100. The lysate was then centrifuged at
15,000 x g for 5 minutes to pellet cellular debris. A Pierce™ Bicinchoninic Acid Assay
Kit from Thermo Scientific (catalog number 23225) was used, according to
manufacturer protocol, to determine protein concentration in the supernatant. Each
sample was analyzed at a dilution of 1:5, 1:10, and 1:20 with PBS and absorbance was
measured at 570 nm. The standard curve for determining protein concentration ranged
from 0 mg/mL to 1 mg/mL.

Assessment of ICAM-1 Levels in Müller glial Cell Culture
A Western blot was used to compare the relative amount of ICAM-1 between treatment
groups. 100 µg of cell lysate was analyzed for each sample. Each sample was
incubated at 95° C for 15 min with 1x sample buffer (10% glycerol, 2% SDS, 0.01%
bromophenol blue, 200 mM Tris-HCl pH 6.8, 20 mM dithiothreitol) to denature proteins.
PBS was added to each sample so that each had a volume of 25 µL. Samples were
separated on a 12% polyacrylamide Mini-PROTEAN ® TGX Precast Gel (Biorad) along
with a protein ladder (Biorad). The gel electrophoresis was performed in running buffer
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(0.3% w/v Tris Base, 1.45% w/v Glycine, 0.1% w/v SDS) at 200 volts for 1 hour to
separate proteins.

Proteins resolved by electrophoresis were transferred to a polyvinyl difluoride (PVDF)
membrane. Prior to transfer, the membrane was soaked in methanol for 2 minutes and
then washed with Transfer Buffer (0.3%w/v Tris, 1.45% w/v glycine, and 10% v/v
methanol). The gel was sandwiched between 2 sponges and filter papers soaked in
transfer buffer and placed into a cassette. Transfer of the proteins proceeded for 16 h
at 100 mA and 4°C. Following transfer, the PVDF membrane was blocked with 1%
bovine serum albumin (BSA) in 1X Tris-buffered saline (TBS; 0.3% w/v Tris-HCl, 0.88%
w/v NaCl) + 0.1% Tween 20 (TBST) for one hour. The membrane was then washed
three times for 10 minutes each with TBST. Next, the membrane was cut at the 50 kDa
mark to incubate portions with their designated primary antibodies. Membranes were
probed overnight with either anti-ICAM (Cell Signaling) at a dilution of 1:500 in TBST
with 1% BSA or anti-GAPDH (Cell Signaling) at a dilution of 1:5000 in TBST with 1%
BSA. After primary antibody incubation, membranes were washed with TBST 3 times
for 10 minutes. A horseradish peroxidase-linked secondary antibody (1:10,000,
Jackson Labs) was incubated for 2 hours with the designated ICAM-1 (85 kDa) portion
of the PVDF membrane and 1 hour with the designated GAPDH (37kDa) portion of the
membrane. For protein detection, SuperSignal™ Chemiluminescent HRP Substrates
were mixed at a ratio of 1:1. The membrane was then coated and allowed to rest at
room temperature in solution for 90 seconds. Afterward, the membrane was Saranwrapped and placed in a film cassette. The film was then exposed in a dark room for
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various time points and developed with an automated TI-2000 developer. Time of
exposure was adjusted to allow for visualization of clear bands. ImageJ software was
used to compare protein levels between groups. GAPDH was utilized as a loading
control; therefore, resolved ICAM-1 levels were normalized to GAPDH for each group.

Concentration of Sample Media for VEGF Analysis
Media was collected after the fifth day of treatment and stored at -80°C. Media samples
were concentrated using 15 mL centrifugal filter spin tubes with a 30 kDa membrane
(MilliporeSigma,). 10 mL of media was loaded into the spin column. Tubes were spun
at 4,000 x g for 10 minutes to reduce sample size to approximately 350 L.
Concentrated samples were stored at -80°C for future analysis.

Assessment of VEGF Concentration
Concentrated cell media samples were analyzed using an eBioscience Rat VEGF-C
Platinum Enzyme-Linked Immunosorbent Assay (ELISA)kit (catalog number BMS626/2)
and compared to a standard curve. All manufacturer’s protocols were followed while
performing this assay. A Bioplex Synergy HT plate reader was utilized to measure
absorbance at 450 nm.

Statistics
Samples for all assays were conducted in duplicate and averaged. A one-way analysis
of variance (ANOVA) was used for determining the significant difference between
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groups. The ANOVA was further followed by a Bonferroni posthoc test. The alpha for
statistical analysis was set at a p-value of 0.05.

IV.

RESULTS

Rationale
Therapeutic effects of PBM have been demonstrated in a variety of disorders, primarily
those in which progression is associated with changes in oxidative stress and
inflammation. In vitro and in vivo research collectively performed by Tang et al. (2013)
and Saliba et al. (2015) indicate that, in models of DR, PBM attenuates the
hyperglycemic induction of oxidative stress and reduces leukostasis (Tang et al. 2013,
Saliba et al. 2015). The inhibition of leukostasis correlated with a reduction in the
relative level of ICAM-1. Although PBM has been studied in DR by examination of
pathological and histological changes, very little is known about the effects of PBM on
intracellular signaling events. To better understand the mechanism of PBM, we
designed studies to determine its action on the transcription factor NF-B. Because
PBM modulates oxidative stress, it is likely that this diminution of oxidative stress will
diminish the activation of NF-B in a model of DR. The purpose of this experiment is to
determine the effect PBM on NF-B activity in a Müller glial cell culture model of DR.
We plan to measure NF-B activity as well as two downstream proteins that are
transcriptionally regulated by NF-B, ICAM-1 and VEGF (Mamputu et al. 2004, Shelton
et al. 2007).
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Part 1. Effects of Photobiomodulation on NF-κB Activity in a Müller glial Cell
Culture

NF-B activity in Müller glial cells cultured in normal (5 mM) glucose or high (25 mM)
glucose, that were either sham treated or treated with 670 nm LED for 180 seconds at a
dosage of 4.5 J/cm2 was quantified using a dual luciferase assay. This assay allows for
a direct measure of NF-B transcriptional activity. When cells were cultured in high
glucose, there was a significant increase in NF-B activity in comparison to cells
cultured in normal glucose (n=4, p<0.0001). As shown in Figure 3, a 70% increase in
luminescence in the high glucose cultured groups was observed in comparison to those
cultured in normal glucose. To analyze Specific Aim 1, the effects of 670 nm LED
treatment for 180 seconds at a dosage of 4.5 J/cm 2 on Müller cells cultured in high (25
mM) glucose was additionally analyzed. After treatment for three days with 670 nm
LED, the activity of NF-B in high glucose cultures of Müller glial cells was significantly
reduced (n=4, p<0.0001). As indicated by a p-value of 1 (n=4), there was no statistical
difference between the degree of NF-B activation in the normal glucose cultured group
receiving sham treatment in comparison to the high glucose group treated with 670 nm
PBM. These findings indicate that 670 nm light completely attenuated the activation of
NF-B induced by hyperglycemia. Furthermore, when cells were cultured in normal
glucose conditions, treatment with 670 nm light did not appear to affect the activity of
NF-B (Figure 3).
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Figure 3: Comparison of NF-κB activity between treatment groups
Bar graph, representing three separate experiments, showing NF-B activity of
Müller glial cells maintained in either normal glucose or high glucose medium.
After three days in culture, cells were collected and lysed for analysis of
luminescence. Data is presented as a measure of luciferase luminescence
normalized to Renilla luminescence (transfection control). Results are presented
as a ratio to activity observed compared to that of the normal glucose, shamtreated group. **p<.0001
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Part 2. Effects of Photobiomodulation on level of ICAM-1 and VEGF
Concentrations

Part 2A: Effects of Photobiomodulation Treatment on ICAM-1 Levels

To analyze the effects of high (25 mM) glucose and treatment with 670 nm LED for 180
seconds at a dosage of 4.5 J/cm2 on the level of ICAM-1 four sets of cells were plated.
These groups were either cultured in normal (5 mM) glucose or high (25 mM) glucose
and received either sham or treatment with 670 nm light. After five days of treatment,
lysates were analyzed by western blot for quantification of ICAM-1. This is longer than
the time frame used for NF-B activity analysis to provide time for gene transcription
and protein translation to occur. As shown in Figure 4, we measured an increase in
ICAM-1 concentrations in cell lysates from cells cultured in high glucose compared to
those cultured in normal glucose. There was considerable inter-assay variability
between replicates in our ICAM-1 assays, and our results did not achieve statistical
significance (n=3, p=.066), likely due to small sample size. We then statistically
analyzed the effects of 670 nm PBM on the relative level of ICAM-1. Data presented
shows that PBM-treated cells cultured in high glucose exhibited a decrease in ICAM-1
levels. We observed a 60% decrease in ICAM-1 concentrations in PBM-treated cells
cultured in high glucose compared to sham-treated cells cultured in high glucose.
These differences were not statistically significant (n=3, .089). Each experiment was
repeated twice. We anticipate that additional experiments will be necessary to observe
a statistically significant difference. In the high glucose treated cells, ICAM-1 was
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Figure 4: Comparison of respective ICAM-1 levels between treatment
groups
(A) Bar graph, representing three separate experiments, showing the percentage
of ICAM-1 in relation to GAPDH of Müller glial cells maintained in either normal
glucose or high glucose medium, which received either PBM or sham treatment.
Cell lysates were collected from Müller glial cells culture for the analysis of ICAM1 concentrations. Cells either received five days of sham treatment or were
treated with 670 nm PBM (n=3) (B) Representative Western blot of ICAM-1 and
GAPDH bands for each treatment group (NS: normal glucose, sham-treated; NT:
normal glucose, PBM treated; HS: high glucose, sham-treated; HT: high glucose,
PBM treated).
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reduced back down to levels comparable to both sham and PBM treated normal
glucose cultured cells (n=3, p=1). Additionally, between the normal glucose cultured
group which received 670 nm light and the normal glucose group, which received sham
treatment there was no significant difference in the relative level of ICAM-1 (n=3, p=1).
Therefore, in the absence of high glucose treatment with 670 nm LED does not affect
the level of ICAM-1.

Part 2B. Effects of 670 nm Photobiomodulation on VEGF concentration in an in vitro
model of DR.

VEGF plays a primary role in the progression of DR. Therefore, the inhibition of VEGF
signaling has been a primary target for the treatment of DR. To assess the effects of
670 nm LED on VEGF concentrations, Müller glial cells were cultured in either high or
normal glucose, with or without 670 nm light treatment. After six days in culture, the
effect of high glucose on VEGF concentration was analyzed using a sandwich ELISA.
No significant differences in VEGF levels were observed between high glucose and
normal glucose medium culture conditions (n=3). Furthermore, 670 nm light treatment
did not alter VEGF levels in either high glucose conditions or normal glucose conditions.
Collectively, data presented in Figure 5 indicates that in a cell culture model of Müller
glial cells, VEGF concentration is not affected by either the concentration of glucose nor
670 nm light treatment.
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Figure 5: Comparison of VEGF concentrations between treatment groups
Bar graph, representing three separate experiments, showing VEGF
concentration of Müller glial cells maintained in either normal glucose or high
glucose medium, which received either PBM or sham treated for five days.
Conditional media was collected from Müller glial for the analysis of VEGF
concentrations. An ELISA was used for detection of VEGF, and concentrations
were calculated from a standard curve.
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V.

DISCUSSION

The objective of this thesis study was to determine the effects of 670 nm light in an in
vitro model of DR. For this investigation, Müller glial cells cultured in high (25 mM)
glucose received 670 nm light at a dose (or fluence) of 4.5 J/cm2. To analyze the
effects of PBM on NF-B transcriptional activity, transfected Müller glial cells were
cultured under high glucose and were either sham-treated or PBM-treated for three
days. The data presented shows that treatment with 670 nm LED significantly reduces
the over-activation of NF-B, which occurred as a consequence of exposure to high
glucose concentrations. Importantly, NF-B concentrations in PBM-treated highglucose-exposed cultures was not different from that measured in cells maintained
under normal glucose. Moreover, in comparison to their sham treated, high glucoseexposed counterparts, there was a 60% decrease in ICAM-1 concentrations. Our in vitro
data on the effects of PBM on ICAM-1 concentrations in high glucose cultured Müller
glial cells was comparable to the in vivo effects of PBM in diabetic rodents (Tang et al.
2013, Saliba et al. 2015). Unexpectedly, we observed no change in VEGF
concentration under high glucose conditions compared to normal glucose cultured cells.
Furthermore, 670 nm light did not affect VEGF concentrations under either glucose
condition. Data indicates that in this cell culture model of DR, VEGF is not regulated
under similar regulatory function as ICAM-1.

Although NF-B is known to have diverse regulatory functions, its over-activation has
shown to be correlated to an increase in oxidative stress and to be of pathological
significance in animal models of DR (Nagai et al. 2007). Treatment with 670 nm LED
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has been assessed in STZ diabetic rat models and shown to attenuate progression and
improve visual acuity (Tang et al. 2013). Additionally, PBM decreased oxidative stress
in both in vivo and in vitro studies of retinal ganglion cells, photoreceptors, retinal
pigment epithelium cells, and Muller glial cells; which was the cell type also utilized for
the present study (Tang et al. 2013). How PBM affects intracellular signaling, including
NF-B transcriptional activity and ICAM-1 or VEGF levels, is addressed in a Müller glial
cell culture model in this study.

Previous in vivo and in vitro studies have demonstrated that a hyperglycemic
environment induces activation of NF-B. Pericytes cultured in high (30 mM) glucose
for 8 h, 24 h, 48 h, or 1 week exhibited elevated levels of the NF-B p65 unit in the
nucleus (Romeo et al. 2002). NF-B concentrations have also been analyzed in retinal
capillaries of diabetic eye donors removed during the nonproliferative stage of DR
development (Romero et al. 2002). Results from these studies revealed a greater
concentration of NF-B inside the nuclei of pericyte cells from diabetic donors in
comparison to pericytes from non-diabetic donors (Romeo et al. 2002). This indicates
increased translocation of NF-B to the nucleus, the site where it is functional.
However, the translocation of NF-B to the nucleus is not necessarily suggestive of
transcriptional activity (Hayashi et al. 1993). To induce DNA binding and transcriptional
activity, NF-B must be reduced by redox regulation (Hayashi et al. 1993). In our study,
a 70% increase in NF-B transcriptional activity in the high glucose cultured, sham
treated groups was observed in comparison to cells cultured in normal glucose and not
receiving treatment (Figure 3). These findings support previous work by Shelton et al.
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(2007) and Shanmugam et al. (2003). Shelton et al. reported elevated NF-B activity in
transfected Müller glial cells after 8 hours in high glucose (25 mmol/L) in comparison to
cells maintained in normal glucose (Shelton et al. 2007). In accordance with this data,
transfected THP-1 (human leukemic monocytes) cells incubated under high glucose for
three days presented with a five-fold increase in NF-B activity in comparison to those
cultured in normal glucose (Shanmugam et al. 2003). However, not all cell types
appear to follow this pattern. Endothelial cells cultured in high (30 mM) glucose for 8
hrs, 24 hrs, 72 hrs, and one week had no significant difference in the translocation of
NF-B to the nucleus when compared to cells cultured in normal glucose culture media
(Romeo et al. 2002). These results suggest that the translocation of NF-B to the
nucleus in response to high glucose appears to be cell type specific.

In addition to the observed increase in NF-B, ICAM-1 levels were also elevated when
Müller glial cells were cultured in high (25 mM) glucose conditions. We measured
ICAM-1 levels by Western blot on samples treated for five days, based on a prior study
by Chen et al. (2012) observing elevated levels of ICAM-1 when cells were cultured in
high glucose for a range of one to seven days (Chen et al. 2012). After six days in high
glucose conditions, a two-fold increase in ICAM-1 concentration relative to levels of
GAPDH was observed (Figure 4). Our findings are in agreement with previous studies.
Elevated levels of ICAM-1 were, as well, observed in STZ diabetic mice in comparison
to non-diabetic control animals (Tang et al. 2013, Elmarakby et al. 2012). Likewise, in a
Müller glial cell culture model of DR, a 4-fold increase in ICAM-1 levels was reported for
cells cultured in high (25 mM) glucose in comparison to cells cultured in normal glucose
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conditions for five days. Unlike prior studies, our data did not reach significance;
however, conducting additional experiments or measuring membrane bound ICAM-1
rather than total protein concentration might enable us to achieve statistically significant
changes. Since ICAM-1 induces its function when membrane bound, this may provide a
better measure of biological significance.

We postulate that the induction of NF-B activity, and the increase in ICAM-1
concentrations, observed in the present study as a result of high glucose exposure
occurs due to an increase in oxidative stress based on the effects of antioxidants in
models of DR (Kowluru et al. 2003). Two months post-induction of diabetes in STZ
diabetic rats the activation of NF-B was increased by 60% in retinal samples compared
to non-diabetic counterparts (Kowluru et al. 2003). Corresponding to this increase in
NF-B activity was a reduction in the antioxidant capacity of superoxide dismutase and
an increase in oxidative stress, as measured by the presence of 8-isoprostane in the
blood and ratio of oxidized glutathione to reduced glutathione (Kowluru et al. 2003).
The increase in NF-B activity and oxidative stress, as well as the reduction in
antioxidant capacity of superoxide dismutase, was partially attenuated in diabetic rats
which were treated with the antioxidant resveratrol (Kowluru et al. 2003). Thus, it is
likely that the observed increase in transcriptional activity may be related to a
hyperglycemic induction in oxidative stress (Kowluru et al. 2003, Kim et al. 2007).

In the progression of DR, the induction of ICAM-1, as a result of NF-B activation
induced by oxidative stress, promotes the movement of leukocytes (leukostasis) and
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subsequent death of endothelial cells (Kowluru et al. 2003, Joussen et al. 2001).
Therefore, inhibition of NF-B, directly or indirectly, may provide a means in which to
control the progression of DR. As discussed, one manner in which NF-B activity can
be modulated is through the reduction of oxidative stress (Kowluru et al. 2003). In a
multitude of models, treatment with light in the NIR range has been shown to diminish
oxidative stress (Tang et al. 2013, Saliba et al. 2015, Silva Macedo et al. 2015,
Purushothuham et al. 2014). Tang et al. (2013) determined the effects of PBM on
oxidative stress in various cell cultures models of DR. For these studies, retinal glial
cells, photoreceptors, Müller glial cells, and retinal pigment epithelial cells were
maintained in 30 mmol/L glucose (Tang et al. 2013). For cells cultured in high (30 mM)
glucose, there was a significant increase in oxidative stress, as indicated by the
presence of superoxide when compared to cells cultured in normal (5 mM) glucose
media (Tang et al. 2013). The effects of hyperglycemic conditions were ameliorated in
groups receiving 670 nm LED treatment for four days at a dosage of 5 J/cm 2 (Tang et
al. 2013).

In STZ-diabetic rats, light treatment was performed at the early onset of DR (7 to 10
days post STZ administration). Animals received 670 nm LED treatment once daily at
an irradiance of 25 mW/cm2 for 270 seconds producing a dose 6.8 J/cm2 for nine
weeks. Treatment with 670 nm LED resulted in decreased superoxide levels in the
retina in comparison to non-diabetic controls (Tang et al. 2013). Similarly, diabetic mice
presented with an increase in retinal superoxide concentrations in comparison to nondiabetic animals, which coincided with enhanced leukostasis and elevated ICAM-1
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concentrations within the retinae of diabetic animals (Tang et al. 2013). Subsequent
studies by Saliba et al. (2015) observed similar results to those presented by Tang et al.
(2013). Animals were either sham treated or were treated with 670 nm LED for ten
weeks at a daily dosage of 5 J/cm2 (Saliba et al. 2015). They observed an increase in
leukostasis, superoxide, and ICAM-1 levels in diabetic mice when compared to nondiabetic control mice. The increase in leukostasis, superoxide, and ICAM-1 induced by
diabetes was ameliorated in groups treated with 670 nm LED (Saliba et al. 2015).
Additionally, these animals had an improvement in retinal function as measured by
ERGs (Saliba et al. 2015). Collectively, this data indicates that PBM attenuates
oxidative stress, which corresponds to an alleviation of leukostasis as a result of
decreased ICAM-1 concentrations. Due to the relationship between oxidative stress,
NF-B, and ICAM-1 in the development of DR, it was likely that this treatment would
promote similar effects on NF-B activity.

To test this, we cultured Müller glial cells under high (25 mM) glucose conditions and
then treated the cells with 670 nm LED at a dosage of 4.5 J/cm2, or sham treated, for
three days. Treatment with 670 nm LED promoted a significant reduction in NF-B
activity and a reduction of ICAM-1 levels in a cell culture of Müller glial cells. As
mentioned earlier, it is suspected that these observations occur as a result of a
reduction in oxidative stress, as shown by Tang et al. (2013) and Saliba et al. (2015).
This theory is supported by work performed by Shelton et al. (2007). Under
homeostasis, glutaredoxin is considered protective and functions to prevent the
irreversible oxidation of proteins. However, in diseases with unresolving oxidative
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stress, such as DR, enhanced glutaredoxin activity may disrupt normal redox regulation
of transcription factors including NF-B. Such a state has been observed in Müller glial
cells incubated in high glucose (Shelton et al. 2007). In Müller glial cells cultured in high
glucose, there was a notable increase in glutaredoxin activity, NF-B transcriptional
activity, and an increase in ICAM-1 levels (Shelton et al. 2007). Additionally, when
glutaredoxin was overexpressed, there was an increase in the nuclear localization of
NF-B (Shelton et al. 2007) Conversely, when glutaredoxin activity was knocked down
in high glucose cultured Müller cells, there was a significant decrease in ICAM-1
(Shelton et al. 2007). These results suggest that the hyperglycemic induction of
oxidative stress enhances the glutaredoxin redox regulation of NF-B. Attenuation of
this oxidative stress by PBM, as presented by Tang et al., could diminish the redox
activity of glutaredoxin and, correspondingly, abate the increased activity of NF-B,
such as that observed in this study (Tang et al. 2013). However, since oxidative stress
was not directly measured in the current study, further work is needed to compare the
effects of PBM on oxidative stress, NF-B, and ICAM-1.

In regards to prior work performed assessing the effects of PBM on the activity of NFB, results presented both in this study and prior studies remain inconclusive. In a
model of burn wound healing 904 nm light modulated the activation of NF-B as
measured by western blot (Gupta et al. 2015). The injury was induced on SpragueDawley rats by an aluminum metal rod heated to 85°C (Gupta et al. 2015). SpragueDawley rats received treatment for seven days for a duration of 3, 10, or 15 minutes
with 904 nm light, or received sham treatment (Gupta et al. 2015). NF-B activity was
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significantly reduced for injured animals, which received treatment with 904 nm light in
comparison to their sham treated counterparts (Mafra de Lima et al. 2009). Conversely,
in a model of airway inflammation treatment with PBM increased the activity of NF-B
(Mafra de Lima et al. 2009). Airway inflammation was induced in bronchi isolated from
male Wistar rats. The bronchi were treated with 650 nm light twice daily for 42 seconds
at a dosage of 1.3 J/cm2 (Mafra de Lima et al. 2009). Treatment with 650 nm light
reduced constriction to the bronchi when airway inflammation was induced. However,
when and NF-B inhibitors were introduced the beneficial effects of 650 nm light was
attenuated. These results suggest that NF-B activation by PBM is important for
therapeutic effects (Mafra de Lima et al. 2009). However, due to the diverse role of NFB in maintaining cellular function, as well as varying effects observed between
wavelengths and dosages further work is needed to better understand the effect of PBM
on NF-B in varying models.

Unexpectedly, we observed that high glucose culture conditions did not significantly
alter VEGF concentrations compared to Müller glial cells cultured in normal (5 mM)
glucose conditions (data representative of three independent experiments). We were
surprised that VEGF was not increased by high glucose in Müller cells, as this does not
compare with observations reported by previous studies. Bai et al. (2009) have
suggested that Müller glial cells are primarily responsible for the increase in VEGF
observed in animal models of DR. In conditional VEGF knockout mice, a Cre/lox
system was used to determine the significance of Müller glial cell-derived VEGF. When
VEGF synthesis was blocked in Müller glial cells of the conditional mice, a 44.5%
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decrease in VEGF retinal concentration was observed in comparison to their WT
counterparts (Bai et al. 2009). However, these results also indicate that more than 50%
of VEGF is attributed to additional sources, including neuronal cells and RPE cells.
Therefore, a pure Müller cell culture system may not provide substantial concentrations
of VEGF to analyze the effect of 670 nm LED treatment. Analysis of VEGF
concentrations in aqueous humor samples from diabetic patients, without PDR,
revealed very low concentrations of this growth factor, suggesting that it may be
challenging to measure VEGF changes above baseline levels (Oh et al. 2010).
Comparison of VEGF concentrations in the aqueous humor, as well, presented no
significant difference between samples collected from non-diabetics, diabetics, or
diabetics with severe non-proliferative DR (Oh et al. 2010). It was not until patients had
developed PDR that a significant increase in VEGF concentration was observed. The
difference in VEGF concentration observed between patients with non-proliferative DR
and PDR was 30 pg/mL (Oh et al. 2010). Therefore, based on findings by Bai et al.
(2009), only half of the change in concentration was a result of Müller glial cells (Bai et
al. 2009, Oh et al. 2010). Therefore, our model may not be representative of PDR. The
changes in the concentration of VEGF may also not be great enough above baseline to
determine statistical differences.

Differences between cell culture models and time points selected for analysis may
account for the variability observed between our results and previous findings in animals
and other cell culture models. For instance, Natarajan et al. (1997) cultured primary
vascular smooth muscle cells in high glucose (25 mmol/L) and normal glucose (5
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mmol/L). Each group of cells were cultured for two passages under selected conditions,
and then a northern blot was performed for detection of VEGF mRNA (Natarajan et al.
1997). High glucose conditions resulted in a 2.5-fold increase in VEGF mRNA in
comparison to cells cultured in normal glucose conditions (Natarajan et al. 1997). In
primary rMC cultured in high glucose (30 mmol/L), both protein and mRNA levels of
VEGF were increased at the time points of 8 hrs, 12 hrs, and 24 hrs (Ya et al. 2012).
However, levels of VEGF in primary rMC decreased from 24 to 48 hours (Ya et al.
2012). Therefore, we may have missed the time point at which VEGF is elevated.

Contrary to these studies, Brooks et al. suggest that high glucose alone may not
effectively induce VEGF synthesis in Müller glial cells (Brooks et al. 2005). Brooks et al.
(2005) analyzed the effects of pH and glucose on VEGF production under normoxic and
hypoxic conditions. After 48 hours, it was observed that when cells were cultured under
hypoxic conditions both glucose and pH had a significant effect on VEGF production
(Brooks et al. 2005). However, if cells were cultured in normoxic conditions for 48
hours, pH and glucose had no measurable effect on VEGF synthesis (Brooks et al.
2005).

Comparison of Ya et al. (2012) and Brooks et al. (2005) protocols indicate two
differences, time course of experiments and serum presence. In work performed by
Natarajan et al. (1997), and Ya et al. (2012) media was supplemented with 0.2% BSA or
0.5% BSA, respectively. In our study and Brooks et al. medium was supplemented with
2% FBS and 10% FBS, respectively. In these studies, hyperglycemia alone was not
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found to induce VEGF (Brooks et al. 2005). Both of these serum supplements may
contain constitutive growth factors, which could affect results of the assays. FBS, in
particular, may contain growth factors unfavorable for analysis of VEGF. In a cell culture
of dermal fibroblasts, 10% FBS was found to upregulate expression of pigment
epithelium-derived factor, which is known to inhibit the synthesis of VEGF (Man et al.
2009, Zhang et al. 2006). Differences in serum type and serum concentrations could
account for the observable difference. In addition to differences in serum, the time
course utilized varied among the studies. A time course analysis, as well as, studies
analyzing differences between culture conditions may help clarify the variability
observed between the current and prior studies.

Our experimental design also allowed us to examine PBM effects in the presence of
normal glucose levels. We show that PBM has no effect on NF-B or ICAM-1 levels in
cells cultured in normal glucose medium (Figure 3 and 4). This suggests that, in the
absence of high glucose, PBM does not have an impact on NF-B transcriptional
activity and relative level of ICAM-1. Thus, in regards to DR, treatment with 670 nm
LED may only have certain effects while in a hyperglycemic state.

Taken together, we show that 670 nm LED treatment may provide therapeutic effects in
models of DR by reducing the increase in NF-B transcriptional activity and the increase
in the level of ICAM-1 induced by high glucose culture conditions. Further research
utilizing animal models will help develop an understanding of the effects PBM has on
intracellular signaling. As mentioned, signaling through the AGE-RAGE pathway also
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plays a role in the development and progression of DR. Animal studies will also allow
for the analyzation of treatment with 670 nm LED in advanced stages of DR, and
confirm if this treatment will have the same effect on transcriptional activity of NF-B
and changes in the level of ICAM-1.

Conclusion and Future Directions
The aim of this study was to determine the effects PBM using 670 nm light for 180
seconds on the activity of NF-B, as well as its effects on concentrations of ICAM-1 and
VEGF. The hypothesis for this study was that 670 nm light will attenuate the
hyperglycemic induction of NF-B and reduce the concentrations of ICAM-1 and VEGF
in a Müller glial cell culture. The data presented in this thesis partially supports the
central hypothesis. Data showed that in the presence of high glucose 670 nm light
treatment significantly reduced NF-B activity. Similar results were also obtained for
ICAM-1. When Müller glial cells cultured in high glucose were treated for five days with
670 nm LED the level of ICAM-1 detected was 60% lower than that observed in high
glucose cultured cells receiving sham treatment. We also analyzed the effects of PBM
on NF-B and ICAM-1 when cells were cultured under normal conditions. Between
normal glucose cultured groups, which received 670 nm light treatment and those which
did not, there was not a significant difference in either transcriptional activity of NF-B or
the level of ICAM-1. Further studies are needed to support these findings due to ICAM1 analysis not reaching statistical differences. Performing a time course study for both
ICAM-1 and NF-B would also better allow a direct comparison of the transcriptional
activity of NF-B to the synthesis of ICAM-1.
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Currently, our data indicate that VEGF may not be regulated by NF-B in our model
system. However, cell culture analysis for the effects of high glucose on VEGF in
previous studies suggests contradictory findings to the data presented (Ya et al. 2012,
Brooks et al. 2005). As suggested above, adjustments to time course and culture
conditions may be needed to be made for further VEGF studies.

Translation into an animal model may also provide the best manner in which to study
the effects of DR. Performing these experiments in an animal model will allow for
examination of changes in the retina, where multiple cell types are present, and cell-cell
contact and paracrine signaling may take place. To do this, the treatment protocol (240
seconds daily, 25 mW/cm2, 6 J/ cm2) previously established by Tang et al. (2013) would
be followed, since therapeutic effects, as indicated in improvements in retinal function,
have been previously established. Changes in NF-B translocation would be measure
from excised retina samples. Furthermore, ICAM-1 and VEGF concentrations can be
measured by an immunoprecipitation assay as described in Tang et al. (Tang et al.
2013). Addition of a NF-B inhibitor would also provide a manner to confirm the relation
between NF-B and ICAM-1 in a model of DR.

In conclusion, the work presented in this study does support that treatment with 670 nm
light has an inhibitory effect on NF-B and reduces the synthesis of ICAM-1. This work
has begun to provide a mechanism of action for treatment with 670 nm light in our
model system. Examining the role of NF-B with and without PBM in an animal will
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allow for further mechanistic insight into PBM. Further elucidation of the mechanism of
action for 670 nm light treatment in a model of DR, will assist in the movement of PBM
therapy to clinical use.
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